TL;DR — PT-141 (generic name Bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan II and optimised for selectivity toward MC4R. Published research has investigated its effects on central nervous system pathways associated with arousal and desire. Unlike PDE5 inhibitors (which act on peripheral vasodilation), PT-141 operates centrally through melanocortin signalling. B.A.B.E LABS supplies PT-141 via THRILL PILL and in the IN HEAT bundle.
What is PT-141?
PT-141 is a cyclic heptapeptide that evolved from early Melanotan II research. Where MT-II activates all five melanocortin receptors non-selectively, PT-141 was specifically developed to emphasise activity at MC4R in the central nervous system.
The molecule was developed by Palatin Technologies and carries the generic international nonproprietary name Bremelanotide.
Mechanism: MC4R and central arousal
MC4R is densely expressed in the hypothalamus, particularly the paraventricular nucleus. Research has long established hypothalamic MC4R signalling as a central node in arousal-pathway neurobiology — distinct from peripheral vascular effects.
What makes PT-141 pharmacologically novel:
Most arousal-related pharmacology historically targets the periphery — nitric oxide signalling, phosphodiesterase inhibition, smooth muscle dilation. PT-141's pharmacology is central: it crosses the blood–brain barrier, binds MC4R, and acts upstream of any peripheral vascular cascade. This makes it a research compound of interest in studies probing the central component of arousal neurobiology.
Differences from Melanotan II:
- MT-II is non-selective across MC1R–MC5R; PT-141 is MC4R-biased
- MT-II's MC1R activity drives melanogenesis (tanning); PT-141's MC1R contribution is lower
- PT-141 was the subject of a regulatory submission (brand name Vyleesi) in the United States — a jurisdictional fact, but note that B.A.B.E LABS supplies the research compound only
Research context:
Published literature on Bremelanotide spans -
- Preclinical primate and rodent models characterising arousal and behavioural endpoints
- Receptor pharmacology studies quantifying MC1R/MC3R/MC4R/MC5R binding ratios
- Clinical trial programmes (not relevant for research supply but useful as background reading)
- MC4R structural biology — PT-141 is cited in crystal-structure studies of the receptor
Why PT-141 is paired with Kisspeptin-10 in In Heat:
The IN HEAT bundle combines PT-141 with CLUCKY. The two compounds act on entirely different nodes of reproductive neuroendocrinology:
- PT-141 — MC4R-mediated central arousal pathway
- Kisspeptin-10 — upstream regulator of GnRH release via GPR54 (KISS1R) signalling
Bundling them supports research programs that probe both the central arousal component and the upstream HPG-axis regulation in parallel.
Purity and testing:
Every Thrill Pill batch is:
- HPLC ≥99% purity
- Mass-spec verified
- Accompanied by a Certificate of Analysis
Storage and reconstitution:
- Lyophilised: –20°C, light-protected
- Reconstituted: 2–8°C, use within the COA window
Research-use disclaimer:
Strictly for in-vitro and laboratory research. Not TGA-approved for therapeutic use. Not for human consumption. See [Research Use](/pages/research-use-only).
FAQs:
Is PT-141 the same as Bremelanotide?
Yes. PT-141 is the development code (Palatin Technologies); Bremelanotide is the INN (international nonproprietary name).
What's the difference between PT-141 and Melanotan II?
Both are cyclic heptapeptides in the melanocortin receptor agonist family, but PT-141 is MC4R-biased while MT-II is non-selective across all five melanocortin receptors.
Why MC4R specifically?
MC4R is the melanocortin receptor most concentrated in the hypothalamic arousal circuitry. Selectivity for MC4R narrows the research-relevant pharmacology to central, rather than peripheral, effects.